GURU.Markets stock price, segment price, and overall market index valuation
The company's share price BioVie Inc.
BioVie is a biotech company focused on treating Alzheimer's and liver disease. Its stock price is highly volatile, driven by news of clinical trials. The chart is a classic biotech story of binary events, where success or failure is everything.
Share prices of companies in the market segment - Pharma liver
BioVie Inc. is a biopharmaceutical company developing drugs to treat neurodegenerative and liver diseases, such as Alzheimer's and ascites. We've categorized it as a "Pharma: Liver" company. The chart below shows how investors assess the risks in these complex areas.
Broad Market Index - GURU.Markets
BioVie is a biotech company developing drugs to treat neurodegenerative and liver diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how BioVie shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
BIVI - Daily change in the company's share price BioVie Inc.
For BioVie Inc., which develops drugs for Alzheimer's and liver disease, daily price changes are a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to assessing risk.
Daily change in the price of a set of shares in a market segment - Pharma liver
BioVie Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with BIVI, which focuses on treating neurodegenerative diseases, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
BioVie is a biotech company specializing in the treatment of liver diseases and Alzheimer's disease. Its shares are known for their high volatility, driven by expectations and clinical trial results. This is a prime example of how a single story can create powerful market ripples.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization BioVie Inc.
For BioVie Inc., the year-to-date performance is a classic biotech drama. Its 12-month market cap is entirely dependent on clinical trial data for its Alzheimer's drug. Its valuation reflects the hopes and risks associated with tackling one of the most complex challenges in modern medicine.
Annual dynamics of market capitalization of the market segment - Pharma liver
BioVie Inc. is a clinical-stage biotech company developing drugs for the treatment of Alzheimer's disease and liver diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the high risks involved.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
BioVie, with its focus on liver disease and Alzheimer's, is an extremely high-risk biotech. Its performance relative to the market is practically a lottery, with success in clinical trials the winning option. The chart reflects binary outcomes, with both a complete loss and a multiple increase possible.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization BioVie Inc.
BioVie is a late-stage biotech company targeting Alzheimer's and liver diseases. Its monthly performance is entirely dependent on the results of its key clinical trials. Data on its drugs are binary events, causing sharp fluctuations.
Monthly dynamics of market capitalization of the market segment - Pharma liver
BioVie is a clinical-stage biotech company developing drugs for the treatment of neurodegenerative diseases (Alzheimer's) and liver diseases (ascites). The chart below illustrates the overall dynamics of the biotech sector, where drug development for such complex diseases carries both high risk and potential.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
BioVie is a biotech company developing drugs to treat Alzheimer's disease and liver diseases. Its shares are extremely volatile and driven solely by news of clinical trials. Their performance is completely disconnected from the broader market, betting on a scientific breakthrough.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization BioVie Inc.
BioVie is a biopharmaceutical company developing drugs for the treatment of Alzheimer's disease and liver diseases. Its weekly stock price is extremely volatile and depends entirely on the results of clinical trials in these complex areas of medicine.
Weekly dynamics of market capitalization of the market segment - Pharma liver
BioVie Inc. develops drugs to treat liver diseases. For companies like these, clinical trial news is a key driver. The chart shows whether BioVie's weekly share price surge is a one-off or reflects overall investor sentiment in the biotech sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
BioVie Inc. is a biotech company whose stock moves in sync with clinical trial news. This chart is a great way to see how its weekly fluctuations are disconnected from overall market trends. Is the company living its own life, or is it being affected by the global sell-off?
Market capitalization of the company, segment and market as a whole
BIVI - Market capitalization of the company BioVie Inc.
The chart of BioVie Inc. is a highly volatile curve of hopes in the fight against Alzheimer's and liver disease. Its market cap reacts sharply to any news about the clinical trials of its experimental drugs. It's a visualization of the enormous risks and potential rewards in the world of biotech.
BIVI - Share of the company's market capitalization BioVie Inc. within the market segment - Pharma liver
BioVie is a biopharmaceutical company focused on the treatment of liver diseases, such as ascites, and neurodegenerative diseases, including Alzheimer's. Within its segment, its market capitalization reflects investor expectations for its drug candidates. The dynamics of this metric mirror the results of clinical trials.
Market capitalization of the market segment - Pharma liver
BioVie is developing drugs to treat Alzheimer's disease and liver cirrhosis. How big is this arena? The chart below is a barometer of the pharmaceutical sector. Its volatile dynamics reflect the enormous risks and potential rewards in finding cures for humanity's most complex diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
The BioVie chart shows the hopes and risks associated with Alzheimer's and liver disease treatments. Its volatile market cap is a visualization of a roller coaster ride, where each clinical trial result can either boost or derail the stock. It's a diagram of the desperate search for a medical breakthrough.
Book value capitalization of the company, segment and market as a whole
BIVI - Book value capitalization of the company BioVie Inc.
The book value of BioVie Inc., which is developing therapies for Alzheimer's disease and liver cirrhosis, is its tangible capital, consisting of drug rights and financial reserves for late-stage clinical trials. The chart below shows how this scientific and financial capital has changed.
BIVI - Share of the company's book capitalization BioVie Inc. within the market segment - Pharma liver
BioVie Inc. is a biopharmaceutical company whose tangible assets are research laboratories focused on developing treatments for Alzheimer's and liver diseases. These R&D centers are its physical base for innovation. The chart shows the share of this specialized scientific infrastructure the company controls.
Market segment balance sheet capitalization - Pharma liver
BioVie is a biotechnology company. Pharmaceuticals, as the graph shows, are both knowledge- and capital-intensive. BioVie focuses on drug development, and its capital is its intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
BioVie's assets are not factories, but capital invested in clinical trials of its drug candidates for the treatment of Alzheimer's disease and liver cirrhosis. The book value reflects the company's financial resources for working in these highly complex and risky areas of medicine.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - BioVie Inc.
BioVie is a biotech company developing drugs for the treatment of Alzheimer's disease and liver diseases. Its market capitalization is a pure bet on the results of its clinical trials. The chart is a barometer of investor hopes and disappointments in these complex therapeutic areas.
Market to book capitalization ratio in a market segment - Pharma liver
BioVie is a biotech company developing drugs for the treatment of neurodegenerative and liver diseases. Its value depends on the results of clinical trials. The chart shows the high market valuation of its scientific potential compared to its current tangible assets.
Market to book capitalization ratio for the market as a whole
BioVie is a biopharmaceutical company targeting liver diseases and Alzheimer's. Its valuation depends entirely on the progress of clinical trials and investor faith in the science behind the drugs. This chart shows how expectations of a future breakthrough create a market value that has almost nothing to do with current assets.
Debts of the company, segment and market as a whole
BIVI - Company debts BioVie Inc.
BioVie is a clinical-stage biopharmaceutical company focused on treating liver diseases and neurodegenerative disorders. Funding parallel clinical programs in such complex areas requires significant capital. This chart shows how the company raises funds to support its expensive research and development.
Market segment debts - Pharma liver
BioVie is a late-stage biotech company developing drugs for the treatment of Alzheimer's disease and liver cirrhosis. Research in these areas is extremely expensive. This chart shows its financial position and ability to fund its key clinical programs until results are achieved.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio BioVie Inc.
BioVie Inc. is a biotech company developing treatments for Alzheimer's and liver disease. This chart shows its financial structure. For a company whose key developments are in the risky clinical stages, any debt is a significant burden. A failed trial could make it unsustainable and lead to bankruptcy.
Market segment debt to market segment book capitalization - Pharma liver
BioVie is a clinical-stage biopharmaceutical company focused on treating Alzheimer's disease and liver diseases. These are among the most challenging areas for drug development. The chart shows the overall debt burden in the sector, highlighting the colossal financial risks and capital requirements the company faces.
Debt to book value of all companies in the market
BioVie Inc. is a clinical-stage biopharmaceutical company working on treatments for Alzheimer's disease and liver cirrhosis, two of the most complex areas of medicine. This chart, reflecting the debt of established businesses, highlights that BioVie's funding is entirely dependent on investors' faith in science and successful clinical trial results, not debt.
P/E of the company, segment and market as a whole
P/E - BioVie Inc.
For BioVie, a biotech developing drugs for liver disease and Alzheimer's, the P/E ratio is not applicable. The company has no profit, and its valuation on this chart is arbitrary. The actual value is a speculative bet on the success of its clinical trials in highly complex areas of medicine.
P/E of the market segment - Pharma liver
BioVie is a clinical-stage biopharmaceutical company developing treatments for neurodegenerative and liver diseases, such as Alzheimer's disease and ascites. This chart shows the average valuation for the sector, providing investors with context for evaluating BioVie's research portfolio.
P/E of the market as a whole
BioVie is a biopharmaceutical company developing treatments for neurodegenerative and liver diseases. Its valuation is a pure bet on the success of its clinical programs. Overall market sentiment, reflected in this chart, is completely irrelevant. The company's fate depends on the effectiveness of its experimental drugs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company BioVie Inc.
BioVie is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease and liver diseases. This schedule reflects the high expectations and risks associated with its clinical trial results. The company's valuation is entirely dependent on the potential success of its lead drug candidates.
%20P%2FE%20BioVie%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-BioVie-Inc.&v=1772628853623 "Chart of the company's future (projected) P/E BioVie Inc.")
Future (projected) P/E of the market segment - Pharma liver
BioVie is a clinical-stage biopharmaceutical company focused on the treatment of liver diseases (ascites) and neurodegenerative diseases such as Alzheimer's. Its valuation relative to other biotech companies reflects investor expectations for its lead candidates, demonstrating how the market views the scientific data and potential of its drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-liver&v=1772628853624 "Future (projected) P/E graph of the market segment - Pharma liver")
Future (projected) P/E of the market as a whole
BioVie is a biopharmaceutical company developing drugs for the treatment of liver disease (ascites) and neurodegenerative diseases such as Alzheimer's. Its valuation is dependent on clinical trial results. This chart shows the overall risk appetite of investors, which is critical for funding companies operating in such complex and risky fields.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772628853627 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit BioVie Inc.
BioVie is a clinical-stage biopharmaceutical company focused on the treatment of liver-related diseases and Alzheimer's disease. The financial metrics presented here reflect investments in breakthrough research. Clinical trial results are the primary driver of its future.
Profit of companies in the market segment - Pharma liver
BioVie Inc. is a biotech company developing drugs to treat liver disease (ascites) and Alzheimer's disease. This chart is a health indicator for the entire biotech sector. It shows how complex and capital-intensive these fields are, and how often research failures impact financial results.
Overall market profit
BioVie is a biopharmaceutical company developing drugs for liver diseases and Alzheimer's disease. Its prospects depend entirely on the results of clinical trials. The failure or success of these trials will have a far greater impact on the company's value than any economic fluctuations shown by this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company BioVie Inc.
BioVie is a biotech company developing drugs for the treatment of liver diseases and neurodegenerative disorders such as Alzheimer's. Its future revenue forecast is a bet on the success of its clinical programs. This chart reflects analyst expectations for its lead candidates and their market potential.
%20profit%20of%20the%20company%20BioVie%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-BioVie-Inc.&v=1772628853648 "Graph of future (projected) profit of the company BioVie Inc.")
Future (predicted) profit of companies in the market segment - Pharma liver
BioVie Inc. is a clinical-stage biotechnology company developing drugs for the treatment of liver-related diseases (ascites) and neurodegenerative disorders such as Alzheimer's disease. This chart shows the outlook for its segment. It illustrates the high risk and potential reward, with success dependent on clinical trial results.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-liver&v=1772628853657 "Graph of future (predicted) profits of companies in a market segment - Pharma liver")
Future (predicted) profit of the market as a whole
The investment climate reflected in this chart is crucial for biotech companies. BioVie, which focuses on treating liver and neurodegenerative diseases, needs capital for research. Economic recovery and risk appetite encourage funding, while recession makes investors cautious.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772628853664 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - BioVie Inc.
BioVie is a biotech company working on treatments for liver diseases and Alzheimer's. This figure, despite minimal revenue, reflects pure hope. Investors are assessing not current sales, but the potential of its drugs to become blockbusters.
P/S market segment - Pharma liver
BioVie is a biopharmaceutical company developing drugs for the treatment of chronic liver diseases, such as ascites, and neurodegenerative diseases, including Alzheimer's. This chart shows the average valuation in the pharmaceutical sector. It reflects investor expectations for the potential of BioVie's drugs to treat serious diseases.
P/S of the market as a whole
BioVie Inc. is a clinical-stage biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's and liver disease. Its value is based on expectations of future revenue. This chart shows the significant premium the market places on biotech valuations for hope compared to companies with actual revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company BioVie Inc.
BioVie Inc. is a clinical-stage biopharmaceutical company developing treatments for chronic liver disease (ascites) and neurodegenerative diseases. Its valuation is dependent on clinical trial results. The chart shows investor confidence in the potential of its drugs to address serious medical problems.
%20P%2FS%20BioVie%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-BioVie-Inc.&v=1772628853675 "The graph of the company's future (projected) P/S BioVie Inc.")
Future (projected) P/S of the market segment - Pharma liver
BioVie Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of chronic liver diseases (cirrhosis, ascites) and neurodegenerative diseases such as Alzheimer's. This chart reflects investor expectations for the results of its key clinical programs compared to other biotech companies.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20liver&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-liver&v=1772628853679 "Future (projected) P/S market segment graph - Pharma liver")
Future (projected) P/S of the market as a whole
This chart reflects expectations for the biotech sector. For BioVie, a company developing drugs for liver disease and Alzheimer's, it's an indicator of investor risk appetite. Market optimism is essential for funding long and complex clinical trials in these critical areas of medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772628853680 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales BioVie Inc.
BioVie is a clinical-stage biopharmaceutical company developing treatments for chronic liver disease (ascites) and neurodegenerative diseases such as Alzheimer's. This chart reflects revenue from partnerships. Future revenue growth will depend on the success of clinical trials and the commercialization of its innovative treatment approaches.
Sales of companies in the market segment - Pharma liver
BioVie Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of chronic liver disease (cirrhosis) and neurodegenerative diseases. This chart shows the financial activity in this sector. BioVie's breakthrough approaches offer hope to patients with serious diseases, moving the entire industry forward.
Overall market sales
BioVie Inc. is a clinical-stage biopharmaceutical company focused on the treatment of liver diseases and neurodegenerative disorders. Its valuation is dependent on research results. The overall economic environment, shown in this chart, influences the investment climate and the availability of capital to fund long-term research and development.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company BioVie Inc.
BioVie Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of chronic liver disease (ascites) and neurodegenerative diseases such as Alzheimer's. The company's future depends on the results of its key clinical trials. This chart reflects analysts' assessments of the company's development potential in these complex areas.
%20sales%20of%20the%20company%20BioVie%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-BioVie-Inc.&v=1772628853724 "Schedule of future (projected) sales of the company BioVie Inc.")
Future (projected) sales of companies in the market segment - Pharma liver
BioVie is a biopharmaceutical company developing drugs to treat neurodegenerative and liver diseases. This chart reflects expectations for the pharmaceutical sector specializing in liver diseases. It shows the potential analysts see in finding therapies for complex chronic conditions.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-liver&v=1772628853726 "Schedule of future (projected) sales of companies in the market segment - Pharma liver")
Future (projected) sales of the market as a whole
BioVie Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for chronic liver disease (ascites) and neurodegenerative diseases. Its valuation is dependent on trial results. This graph, reflecting the state of the economy, influences investor risk appetite, which is critical for biotech financing.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772628853736 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality BioVie Inc.
BioVie is a biotech company developing drugs to treat liver diseases such as ascites. This chart shows the company's financial performance in late-stage clinical trials. Negative values represent investments needed to complete research and apply for approval, which could unlock access to a larger market.
Market segment marginality - Pharma liver
BioVie Inc. is a biotech company developing drugs for the treatment of liver diseases, such as ascites, and neurodegenerative disorders. For a clinical-stage company, this chart is an indicator of potential. It shows the average profitability in the pharmaceutical sector that BioVie could aspire to if its therapeutic programs are successful.
Market marginality as a whole
BioVie is a clinical-stage biopharmaceutical company focused on the treatment of liver diseases and neurodegenerative disorders. This overall market profitability chart is irrelevant to the company. The company's future depends solely on the results of clinical trials and regulatory decisions. Its success is determined by science, not economic cycles.
Employees in the company, segment and market as a whole
Number of employees in the company BioVie Inc.
BioVie is a clinical-stage biopharmaceutical company developing drugs for the treatment of Alzheimer's disease and liver diseases. This chart shows a small but dedicated team of scientists and physicians. Their size reflects their focus on key clinical programs.
Share of the company's employees BioVie Inc. within the market segment - Pharma liver
BioVie Inc. develops treatments for neurodegenerative diseases such as Alzheimer's and liver disease. This chart shows the percentage of leading scientists and clinicians specializing in these complex therapeutic areas that the company attracts. It reflects its concentration of scientific expertise in the fight against serious age-related diseases.
Number of employees in the market segment - Pharma liver
BioVie Inc. is a clinical-stage biopharmaceutical company developing drugs for the treatment of chronic liver diseases and neurodegenerative disorders such as Alzheimer's. This chart shows how biotech companies are working to address the most complex challenges facing the aging population, attracting top scientists.
Number of employees in the market as a whole
BioVie Inc. develops drugs for liver diseases, solving serious medical problems. The healthcare sector, as illustrated by the overall employment trends in this chart, remains a pillar of the economy. BioVie's research not only brings hope to patients but also supports employment in the complex and expensive field of clinical trials.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company BioVie Inc. (BIVI)
BioVie is a clinical-stage biotech company specializing in the treatment of Alzheimer's disease and liver diseases. This chart represents a pure intellectual capital valuation. The company's value is based solely on the potential of its drug candidates. The chart shows how highly the market values these potential drugs, developed by a small team of scientists, per employee.
%20of%20the%20company%20BioVie%20Inc.%20(BIVI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-BioVie-Inc.-BIVI&v=1772628853775 "Chart of market capitalization per employee (in thousands of dollars) of the company BioVie Inc. (BIVI)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma liver
BioVie Inc. is a biotech company focused on treating liver diseases and neurological disorders. Its market cap reflects expectations for clinical trials. This chart shows how highly the market values the potential generated by a small scientific team. This is an indicator of investor confidence in their scientific platform compared to other biopharmaceutical companies.
%20by%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-liver&v=1772628853797 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma liver")
Market capitalization per employee (in thousands of dollars) for the overall market
BioVie Inc. is a biopharmaceutical company developing treatments for neurodegenerative and liver diseases. This chart shows the average market value generated by one researcher. It highlights the high valuation of scientific potential in complex medical fields.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772628853816 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company BioVie Inc. (BIVI)
BioVie is a clinical-stage biotech company focused on treating Alzheimer's and liver diseases. This chart shows the net loss per employee, reflecting how much the company is burning through on each scientist trying to solve complex medical problems.
%20Chart%20BioVie%20Inc.%20(BIVI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-BioVie-Inc.-BIVI&v=1772628853845 "Company Profit Per Employee (in thousands of dollars) Chart BioVie Inc. (BIVI)")
Profit per employee (in thousands of dollars) in the market segment - Pharma liver
BioVie Inc. is a biopharmaceutical company developing drugs for the treatment of liver diseases, particularly ascites. Its activities are focused on clinical trials. For such companies in the development stage, this graph often shows negative earnings per employee, reflecting significant investments in the scientific team and research in anticipation of breakthroughs and commercialization.
%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-liver&v=1772628853850 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma liver")
Profit per employee (in thousands of dollars) for the market as a whole
BioVie (BIVI) is a clinical-stage biotech company developing drugs for the treatment of neurodegenerative diseases (Alzheimer's) and liver diseases (ascites). It's an R&D company. This chart shows the average profitability per employee across the market. For BIVI (which is not yet profitable), this is a benchmark: in biotech, IP can significantly exceed this average if successful.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772628853867 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee BioVie Inc. (BIVI)
BioVie is a clinical-stage biopharmaceutical company specializing in the treatment of liver diseases and Alzheimer's disease. This chart reflects the expectations of investors and the team. The current low values are typical for biotech, but they could change dramatically if clinical trials are successful.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-BioVie-Inc.-BIVI&v=1772628853868 "Sales chart per company employee BioVie Inc. (BIVI)")
Sales per employee in the market segment - Pharma liver
BioVie is a clinical-stage biotech company focused on treating Alzheimer's disease and liver disease (ascites). Revenue is not yet available. This chart shows the average revenue per employee in the segment, which serves as a benchmark for commercial pharmaceutical companies. It provides context for assessing the effectiveness of BioVie's workforce within the industry.
Sales per employee for the market as a whole
BioVie is a clinical-stage biotech company focused on the treatment of Alzheimer's disease and liver diseases. The company has no commercial revenue. This metric currently doesn't reflect its value, as the entire team is focused on clinical trials rather than sales.
Short shares by company, segment and market as a whole
Shares shorted by company BioVie Inc. (BIVI)
BioVie is a biotech company betting on the treatment of Alzheimer's and liver diseases. The company has already announced the failure of key Alzheimer's trials. This chart shows the bets that the company has no more promising assets. Bears are certain that after the failure of its flagship drug, the company has no future.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-BioVie-Inc.-BIVI&v=1772628853884 "Short Shares Chart for the Company BioVie Inc. (BIVI)")
Shares shorted by market segment - Pharma liver
BioVie Inc. is a biotech company developing drugs to treat liver-related diseases (ascites) and Alzheimer's disease. This chart shows the overall short position in the biotech sector. Its rise reflects investor skepticism regarding the success of clinical trials in complex areas such as liver cirrhosis and neurodegeneration.
Shares shorted by the overall market
BioVie is a biotech company working on complex diseases (Alzheimer's, liver disease). This chart shows the overall market pessimism. For investors, this is a high-risk area. Market fear means that failure in a key trial (which often happens with Alzheimer's) will not be forgiven and will lead to collapse.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator BioVie Inc. (BIVI)
This chart shows BioVie's last hope in the fight against Alzheimer's and liver disease. The company failed in a key Phase 3 Alzheimer's trial, sending its shares into oversold territory (below 30). Now, "overheating" (above 70) can only be achieved by a miracle—either a successful post-analysis of old data or a breakthrough in their liver drug.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-BioVie-Inc.-BIVI&v=1772628853899 "RSI 14 indicator chart for the company's stock BioVie Inc. (BIVI)")
RSI 14 Market Segment - Pharma liver
BioVie (BIVI) is a "biotech" company focused on liver (ascites) and Alzheimer's. The "Pharma liver" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand whether BIVI's growth is due to its R&D or whether the entire biotech sector is overheated.
RSI 14 for the overall market
BioVie (BIVI) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BIVI (BioVie Inc.)
BioVie is a biotech company developing drugs for the treatment of Alzheimer's disease and liver disease (ascites). This chart shows the analysts' average 12-month forecast. It represents their collective bet on clinical trial success in two extremely complex yet enormous therapeutic areas.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BIVI-BioVie-Inc.&v=1772628853905 "A chart showing analyst consensus forecasts for the expected stock price. BIVI (BioVie Inc.)")
The difference between the consensus estimate and the actual stock price BIVI (BioVie Inc.)
BioVie is a biotech company developing drugs to treat severe liver diseases (ascites) and neurodegenerative diseases (Alzheimer's). This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their confidence in these complex but significant R&D programs.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BIVI-BioVie-Inc.&v=1772628853916 "A chart showing the difference between the consensus forecast and the actual stock price. BIVI (BioVie Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma liver
BioVie is a biotech company going all-in on the most challenging R&D areas: Alzheimer's disease and liver cirrhosis (NASH). This chart displays analysts' overall expectations for the entire sector (including liver pharma). It shows whether experts believe a breakthrough can be achieved in the R&D "graveyard."
Analysts' consensus forecast for the overall market share price
BioVie is a biotech company developing drugs to treat Alzheimer's disease and complications of liver cirrhosis (ascites). This is a high-risk area with long development cycles. This chart reflects the overall risk appetite in the market. For BioVie, whose value is based on future expectations, the overall optimism of analysts is critical to funding multi-year trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index BioVie Inc.
BioVie is a clinical-stage biotech whose fate is tied to two bets: an Alzheimer's treatment (NE3107) and a liver cirrhosis treatment (BIV201). It's an R&D business with binary risk. This chart is a pure indicator of faith in their science. It doesn't reflect current sales (they don't have any), but rather a speculative estimate of their R&D progress and (very risky) clinical trial data.
AKIMA Market Segment Index - Pharma liver
BioVie (BIVI) is a clinical-stage biopharmaceutical company targeting two complex areas: Alzheimer's disease and liver disease (ascites) associated with cirrhosis. The chart shows the average index for the segment, helping investors assess how BioVie's risks in these complex areas compare to the sector average.
The AKIM Index for the overall market
BioVie is a biotech company developing treatments for liver disease (ascites) and neurological disorders (Alzheimer's). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative scientific story with a dual focus compares to overall economic trends.
